Dow, S&P 500, Nasdaq Decline Amid Hot Inflation Data, AI Selloff: CRWV, NBIS, NVDA, IBRX Stocks In Focus
U.S. stock indexes fell Wednesday after higher-than-expected inflation data raised Fed rate hike concerns. The Nasdaq Composite dropped 1.88%, while the Dow and S&P 500 declined 0.09% and 1.11%, respectively. Semiconductor stocks were hit hard, with Nvidia (NVDA) down 3% and the SOXX ETF falling 4.5%. CoreWeave (CRWV) and Nebius (NBIS) also declined over 15% and 10% respectively, due to a Gartner report on neoclouds. ImmunityBio (IBRX) rose after FDA approval of its drug Anktiva.
How this was made
The 30-second read
Why it matters
The CPI data and sector weakness combined to push major indexes lower, with specific stocks reacting to company‑specific news.
Market read
Macro inflation data and semiconductor sector stress drove a broad market decline, while select stocks moved on company‑specific catalysts.
What to watch
Potential resilience in demand for AI infrastructure despite short‑term sentiment, and the impact of Chinese DRAM competition on long‑term chip margins.
Background
September CPI showed 0.6% monthly rise and 3.7% annual, raising Fed rate‑hike odds. Semiconductor sector suffered a sell‑off after South Korean chip declines.
Ticker impact
CoreWeave shares plunged >15% after Gartner forecasted limited independent neocloud operations by 2030.
downward pressure from sector sell‑off and negative analyst outlook
The sharp drop and negative Gartner outlook suggest further downside in the near term.
Nebius Group shares fell >10% following the same Gartner report on neoclouds.
downward pressure as investors react to the Gartner warning
The stock moved sharply lower on the same catalyst, indicating continued bearish sentiment.
Nvidia dipped 3% after a broader semiconductor sell‑off triggered by South Korean chip stocks.
downward pressure from sector weakness
NVDA’s move mirrors the broader chip sell‑off, suggesting further near‑term weakness.
ImmunityBio rose after FDA approval of its immunotherapy drug Anktiva.
upward pressure from regulatory approval
FDA approval is a material catalyst that typically supports share price gains.
Market effects
Higher inflation and CPI data increase rate‑hike expectations, pressuring growth‑sensitive sectors like tech and AI.
U.S. futures down; Asian markets opened lower, especially South Korea's chip sector.
Broad market sell‑off driven by inflation surprise and semiconductor weakness.
Counterpoint
If inflation eases later, rate‑hike expectations could recede, providing a rebound opportunity for AI and chip stocks.
Key entities
- RegulatorFederal Reserve
Higher inflation fuels expectations of a rate hike.
- Analyst FirmGartner
Forecasted limited independent neocloud operations, impacting CoreWeave and Nebius.
